Earlier blood-test detection could help identify pancreatic cancer patients who need more aggressive treatment, an expert ...
A blood test may help identify which patients with colorectal cancer that has spread to the liver are most likely to benefit from chemotherapy after surgery, according to research presented today at ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National ...
The U.S. Multi-Cancer Early Detection Market is projected to grow from USD 0.24 Billion in 2025 to USD 1.18 Billion by 2035 ...
NCCN now recognizes personalized, tumor-informed ctDNA-MRD as a prognostic and predictive biomarker in MIBC, extending ...
SAN FRANCISCO — A blood test that measures circulating tumor DNA (ctDNA) can help to identify those patients with resectable colorectal cancer who are most likely to derive the most benefit from ...
The nonsteroidal anti-inflammatory (NSAID) class of drugs, often used to treat pain and fever, includes medications like aspirin that have shown potential in CRC treatment. NSAIDs target ...
Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You ...
At the Miami Breast Cancer Conference, Dr. Heather A. Parsons shared growing evidence for the prognostic value of circulating tumor DNA. We are at a critical crossroads for the clinical use of ctDNA ...
This transcript has been edited for clarity. Cheryl Lee, MD: Welcome to Medscape InDiscussion. I'm Dr Cheryl Lee. Today we'll be talking about circulating tumor DNA, or ctDNA, testing as the next step ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results